Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of ...

PLC reported the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase 2b clinical trial with ...

Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...

"Imvax secures $29m to support Phase IIb glioblastoma therapy trial" was originally created and published by Clinical Trials ...

placebo-controlled Phase 2b trial of GH001 in treatment-resistant depression (TRD). To access the conference call, please register in advance here. A live webcast of the call will be available ...

Akero Therapeutics has revealed preliminary outcomes from its Phase IIb study of EFX in individuals with compensated ...

Dr. Villy Valcheva, CEO of GH Research, expressed optimism about the trial's results, stating, "Today, as we share our unprecedented positive Phase 2b data, we celebrate a significant milestone in our ...

Dogwood Therapeutics, Inc. announced that it will begin dosing patients in its Phase 2b clinical trial, HALT-CINP, in Q1 2025 to study Halneuron®, a novel Nav 1.7 inhibitor aimed at treating ...

Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression. The stock rose 5.2%, to $11.15, in after-hours trading on Friday ...

The trial confirmed linsitinib's favorable safety profile, with no QTc prolongation and manageable adverse events. Late-stage ...

Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...